BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Merck (NYSE:MRK) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. Analysts anticipate a profit of $1.57 per share (-26.3% Y/Y) on revenue of $16.51B (+3.2% Y ...

Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Keytruda racked up a stunning $25 billion in sales last year ... Stocks don't get much riskier than Summit Therapeutics. At ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

Keytruda is now under threat not only from ... a further potential $1.7 billion in developmental, regulatory and commercial milestone payments. Other issues that affected performance were a ...

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...